



Livmarli in India

The CDSCO named-patient coordination pathway — indicative 2026

RARE DISEASE · CHOLESTATIC PRURITUS (ALAGILLE / PFIC)

The clinical situation

Livmarli (maralixibat) is an oral selective ileal bile acid transporter (IBAT) inhibitor FDA-approved for cholestatic pruritus in Alagille syndrome (ALGS) in patients three months and older and for progressive familial intrahepatic cholestasis (PFIC) in patients five years and older. Manufactured by Mirum. Dosing is weight-based once or twice daily as an oral solution. Pre-treatment workup covers genetic confirmation (JAG1/NOTCH2 for ALGS; ATP8B1/ABCB11/ABCB4 for PFIC), baseline LFTs, fat-soluble vitamin levels, and pruritus scoring per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your paediatric hepatologist documents ALGS or PFIC diagnosis, genetic confirmation, pruritus severity, and Livmarli rationale.
- 2 Baseline workup.** LFTs, fat-soluble vitamin levels, bile acid profile, pruritus scale per FDA labelling.
- 3 CDSCO named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, weight-based dosing plan, and chain-of-custody commitment.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with controlled-ambient shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the oral solution; weight-based dosing schedule established with the treating physician.

Indicative economics

Reference US cash-pay range: USD 380,000–450,000 per year of Livmarli (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete CDSCO application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Mirum authorised distribution.

Documentation. Physician kit tailored to CDSCO review, with ALGS/PFIC genetic confirmation and fat-soluble vitamin monitoring annex. **Logistics.** Controlled-ambient internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through monthly refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Livmarli × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/livmarli-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team